A panel of the US FDA has recommended that biotechnologist Novavax’s corona vaccine be approved for adults. If the FDA follows the panel’s recommendation, which it usually does within days, Novavax will become the fourth US-approved corona vaccine, alongside those from Pfizer/BioNTech, Moderna and Johnson & Johnson (Janssen).
Provided the Covid-19 vaccine is approved, Novavax hopes to ship “millions of doses” of it to its US warehouses by the end of June, board member John Trizzino said. The company produces the vaccines with its Indian partner, the biotechnologist Serum Institute of India.
Novavax’s two-shot vaccine is a so-called protein vaccine: a type of vaccine that uses technology that has been used for decades to fight diseases such as the flu. That should especially reassure the approximately 27 million American adults who have yet to be vaccinated. They would not dare to try the successful and popular vaccines from Pfizer and Moderna because of safety concerns, although these vaccines have been found safe by experts – including the regulator FDA.
The assumption that vaccine refusers would see more in Novavax has failed to materialize in the EU, where the Novavax vaccine is already approved and available. Of the approximately 12.6 million doses of Novavax vaccine distributed in the EU since the end of December, only approximately 220,000 doses of the double vaccination have been administered.
Also in the Netherlands there is hardly any enthusiasm for the protein vaccine. Our country bought 840,000 doses of the vaccine for approximately 15 million euros. By mid-April, less than a thousand shots had been taken.
Free unlimited access to Showbytes? Which can!
Log in or create an account and never miss a thing from the stars.